N/A
N=17
Sing for Your Saunter - Dementia Supplement
Parkinson Disease · Parkinson Disease Dementia
Bottom Line
View on ClinicalTrials.gov: NCT04518917 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcome: Primary: Velocity — .977; .960; 1.042; 1.011 meters per second
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Mentally Singing (Behavioral); Listening to music (Behavioral)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- Washington University School of Medicine
- Primary completion
- May 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Velocity |
.977; .960; 1.042; 1.011; 1.070; 1.072 | — |
| PRIMARY Stride Length |
1.085; 1.089; 1.116; 1.103; 1.130; 1.130 | — |
Summary
Older adults, and particularly those with Parkinson disease (PD), may experience walking difficulties that negatively impact their daily function and quality of life. People that have PD plus dementia are also likely to experience walking difficulties. This project will examine the impact of music and mentally singing on walking performance, with a goal of understanding what types of rhythmic cues are most helpful. Pilot work from the investigators suggests that imagined, mental singing (i.e., singing in head) while while walking helps people walk faster with greater stability, whereas walking to music also helps people walk faster but with reduced stability.
In this study, the investigators will recruit people who have PD plus dementia. The investigators will compare walking while mentally singing and walking while listening to music, using personalized cues tailored to each person's walking performance. The investigators hypothesize temporal variability of gait will be lower in the mental singing and singing conditions compared to listening to music; and that mental singing, singing, and listening to music will elicit similar improvements in stride length.
Eligibility Criteria
Inclusion Criteria
- at least 30 years of age
- diagnosis of idiopathic, typical Parkinson disease according to the UK Brain Bank Criteria
- Hoehn & Yahr stages 2-3 (mild to moderate disease severity)
- normal or corrected hearing
- stable on all PD medications for at least 2 months prior to study entry
- dementia as defined by a Clinical Dementia Rating (CDR) score of 0.5-1.0 (very mild to mild dementia)
- score of ≥ 1 on the MDS-UPDRS-III Item #10 indicating observable gait impairment
- a score of 1 or less on item #7 on the freezing of gait questionnaire
- able to walk for 10 continuous minutes independently
Exclusion Criteria
- diagnosis of any other neurological condition
- unstable medical or concomitant illnesses or psychiatric conditions which, in the opinion of the investigators, would preclude successful participation
- cardiac problems that interfere with ability to safely participate (i.e., uncontrolled congestive heart failure, myocardial infarction in past 6 months, complex cardiac arrhythmias, significant left ventricular dysfunction, dyspnea on exertion, chest pain or pressure, resting tachycardia (>100 beats/min); uncontrolled BP (resting systolic BP >160 mmHg or diastolic BP >100 mmHg))
- orthopedic problems in the lower extremities or spine that may limit walking (i.e., severe arthritis, spinal stenosis)
- uncontrolled tremor or dyskinesia while on PD medications
Data sourced from ClinicalTrials.gov (NCT04518917). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.